8th July 2026 by Sarah Thomas
The statistics surrounding breast cancer in younger people are a stark wake-up call. Globally, cancers in young adults under 50 rose by nearly 79% over a thirty-year period. More alarmingly, individuals under 50 are twice as likely to be diagnosed with late-stage breast cancer than someone in their 60s. For those under 25, that risk triples. Younger people are frequently unaware of their symptoms, routinely dismissed by healthcare professionals, and structurally excluded from clinical research.
It was to confront these very disparities that the CoppaFeel! national conference in London brought together leading voices across healthcare, policy, research, the media, and the third sector. This flagship, solutions-focused event was specifically designed to move the needle on younger people's outcomes in breast cancer prevention, diagnosis, and treatment. Marking the launch of a critical publication examining the current state of youth-focused oncology, the conference served as a vital platform to explore how policy and medical practice must evolve to save young lives.
Representing the secondary breast cancer community as a cancer researcher and the Director of Research and Programmes at Make 2nds Count, I was privileged to lead a session at this national forum on the support needs of people diagnosed with secondary breast cancer below screening age.
With next-generation therapeutics, younger patients are living longer on active, lifelong lines of therapy. It is time our support structures evolved to reflect what it truly means to live a full life with an incurable illness in your 20s, 30s, or 40s.
Here are the five critical, evidence-based realities we explored at the conference that define the unique needs of this community:
The idea of a person being “too young” to have breast cancer is a deeply worrying myth. Biologically, patients diagnosed under 50 are statistically predisposed to present with more aggressive phenotypes and advanced disease. Yet, because they sit entirely outside routine NHS screening guidelines, they are frequently faced with a low level of clinical suspicion. This dangerous combination of aggressive biology and delayed recognition directly drives devastating diagnostic delays.
Living with secondary breast cancer means navigating continuous treatment cycles and monitoring. For a younger person, this triggers what is often called the "triple burden": fighting to preserve stable employment, managing the practicalities of caring responsibilities, and enduring the severe financial strain that comes alongside the diagnosis.
This creates an acute psychological weight. Research data shows that 44% of younger women with de novo secondary breast cancer suffer from severe, persistent anxiety, and 20% meet the clinical criteria for depression. Traditional support services are excellent at managing side effects, but they often leave these holistic elements and psychological burden completely unaddressed - which is typically where charities step in to fill the gap.
The economic impact of the disease is deeply skewed against those below screening age. Data highlights that the annual cost of lost work and home productivity due to secondary breast cancer averages nearly £4,000 per year for women under 45, compared to just over £500 per year for people aged 65 and over.
This younger age group are in their peak career-building years and have had less time to accumulate wealth, get on the property ladder, or secure employment enhancements in pay, pension or leave. Yet, they face the highest out-of-pocket costs for daily living expenses, travel for treatment, and childcare.
42.5% of younger breast cancer patients experience severe decision regret about their treatment further down the line. Crucially, the data shows this regret is rarely tied to the clinical failure of a drug. Instead, it is driven by poor communication and the patient feeling excluded from treatment choices.
A foundational element of decision-making in secondary breast cancer is how patients balance extending life against the erosion of its quality. For a younger age group, impacts on employment and family dynamics are the most powerful drivers in personal decision-making. This can impact a patient’s willingness to tolerate side effects and adhere to an intensive treatment schedule.
All patients, regardless of age, deserve autonomous, collaborative shared decision-making surrounding their care. In particular, younger patients value highly detailed, nuanced communication about living long-term alongside cancer. But instead, the focus in clinical appointments is often 'fighting' the disease, rather than being equipped to live with it.
Every single person living with secondary breast cancer deserves the peace of mind that no stone has been left unturned in their care. Yet, currently, only about 14% of UK patients are offered access to clinical trials, despite massive stated interest from this demographic. Data ageism means that the unique impact, dosing requirements, and side effects of new therapies on younger bodies remain under-represented in clinical studies.
At Make 2nds Count, we see these gaps in the care pathway every single day. While the healthcare professionals handle the physical side of the disease, charities must step in to build the holistic safety net around the community.
It is why programmes like Tea & Chat are so vital. Currently providing a psychological and community lifeline to over 500 individuals across the UK, Tea & Chat gives patients an opportunity to find their ‘tribe’ and access local support whenever they need it.
Younger people living with secondary breast cancer are not passive bystanders in their care. They are the innovators, the collaborators, and the true drivers of future oncological research. It is time we match their resilience with an unyielding commitment to structural equity.
-
To learn more about our programmes, and how we are working to change the landscape for those living with secondary breast cancer, explore the rest of the Make 2nds Count website or reach out to us at hello@make2ndscount.co.uk.
Donate